newsfilter
← Latest News
Business Wire·

GoodRx Reports Second Quarter 2025 Results

Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we,"